Deramiocel (CAP-1002)

Name: Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Economic impact of diagnostic testing
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Manufacturer: Capricor Therapeutics
Regulatory submission: Class 2 BLA resubmission submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Duchenne muscular dystrophy

Economic impact of diagnostic testing

1 evidence topic · 1 source

Disease-level newborn-screening model

“Newborn screening via CK testing and genetic testing would cost an estimated $392,061 and $447,170 per life year gained, respectively.” (opens the source at this quote in a new tab)